Posttransplantation human herpesvirus-8 (HHV8)/Kaposi sarcoma herpesvirus (KSHV) primary infection and/or reactivations are associated with uncommon and sometimes fatal, neoplastic, and non-neoplastic diseases. In the context of human immunodeficiency virus (HIV) infection, MCD is associated with human herpesvirus 8 (HHV8) infection. A healthy immune system involves a complex and interconnected network of cells and inflammatory messengers (cytokines), which signal for the immune system to activate. But a July 2008 letter to the editor that appeared in Nature suggested that that may not always be the case and that one day there may be a herpes cure. SYLVANT is an IL-6 antagonist biologic therapy administered as an intravenous (IV) infusion once every three weeks. SYLVANT is the first approved treatment in the U.S. Demographic, clinical features and treatment results were reviewed retrospectively in all patients. Note: In calculating the moving wall, the current year is not counted.
Prolonged compromise of immune function, through conditions such as HIV/AIDS or through IMMUNOSUPPRESSIVE THERAPY such as occurs following ORGAN TRANSPLANTATION, allows HHV-8 to replicate (reproduce itself by taking over healthy cells) and cause Kaposi’s sarcoma. Therapy directed at the IL-6 receptor4,5 as well as monoclonal antibodies directed against IL-6 itself have shown clinical activity5-7 in MCD. After history-taking and a medical examination, medical imaging scans will help to inform a diagnosis, which can be confirmed definitively through laboratory analysis of a tumor sample. The pleural effusion completely resolved following six cycles of R-CHOP therapy, and the patient remained in continuous, complete remission for the next nine years, eventually dying from complications of late-onset diabetes with no evidence of recurrent lymphoma. De Jong RB, Kluin PM, Rosati S, Van Haelst PL, Sprenger HG, Van Spronsen DJ: Sustained high levels of serum HHV-8 DNA years before multicentric Castleman’s disease despite full suppression of HIV with highly active antiretroviral therapy. Additionally, there are rare reports of some of EBV and HHV-8 positive LPDs occurring in the absence of immunodeficiency 10,17. The etiology of UCD is poorly understood, and there is usually no excess interleukin-6 (IL-6) secretion.